KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Payables (2017 - 2025)

Novartis Ag (NVS) has disclosed Payables for 9 consecutive years, with $5.1 billion as the latest value for Q4 2025.

  • Quarterly Payables fell 1.46% to $5.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 billion through Dec 2025, down 1.46% year-over-year, with the annual reading at $5.1 billion for FY2025, 1.46% down from the prior year.
  • Payables hit $5.1 billion in Q4 2025 for Novartis Ag, down from $5.2 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.5 billion in Q4 2021 to a low of $5.1 billion in Q4 2025.
  • Historically, Payables has averaged $5.7 billion across 5 years, with a median of $5.6 billion in 2023.
  • Biggest five-year swings in Payables: increased 1.14% in 2021 and later decreased 7.64% in 2023.
  • Year by year, Payables stood at $6.5 billion in 2021, then fell by 6.87% to $6.0 billion in 2022, then decreased by 7.64% to $5.6 billion in 2023, then decreased by 6.05% to $5.2 billion in 2024, then fell by 1.46% to $5.1 billion in 2025.
  • Business Quant data shows Payables for NVS at $5.1 billion in Q4 2025, $5.2 billion in Q4 2024, and $5.6 billion in Q4 2023.